1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > PharmaPoint: Rheumatoid Arthritis - Current and Future Players

PharmaPoint: Rheumatoid Arthritis - Current and Future Players

Summary

GlobalData has released its pharma report, “PharmaPoint: Rheumatoid Arthritis - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Rheumatoid Arthritis Market. The report identifies and analyses the key companies shaping and driving the global Rheumatoid Arthritis market. The report provides insight into the competitive Rheumatoid Arthritis landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData’s team of industry experts.

Scope

- Investigation of current and future market competition for Rheumatoid Arthritis
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Rheumatoid Arthritis sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Rheumatoid Arthritis market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Rheumatoid Arthritis market landscape? Identify, understand and capitalize

Table Of Contents

PharmaPoint: Rheumatoid Arthritis - Current and Future Players
1 Table of Contents
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
2.3 Upcoming Related Reports 16
3 Market Outlook 17
3.1 Global Markets 17
3.1.1 Forecast 17
3.1.2 Drivers and Barriers - Global Issues 22
4 Current and Future Players 25
4.1 Trends in Corporate Strategy 28
4.2 Company Profiles 29
4.2.1 AbbVie 29
4.2.2 Pfizer 31
4.2.3 Amgen 34
4.2.4 Johnson and Johnson 37
4.2.5 Eli Lilly 39
4.2.6 Bristol-Myers Squibb 41
4.2.7 UCB 43
4.2.8 Roche 45
4.2.9 GlaxoSmithKline 47
4.2.10 Novartis 49
4.2.11 Sanofi 51
4.2.12 AstraZeneca- MedImmune 53
4.2.13 Astellas 55
4.2.14 Vertex 57
4.2.15 Daiichi Sankyo 59
5 Appendix 62
5.1 Bibliography 62
5.2 Abbreviations 67
5.3 Methodology 70
5.4 Forecasting Methodology 70
5.4.1 Diagnosed RA Patients 70
5.4.2 Percentage of Drug-Treated Patients 71
5.4.3 General Pricing Assumptions 71
5.4.4 Generic and Biosimilar Erosion 73
5.5 Primary Research - KOLs Interviewed for This Report 73
5.6 Primary Research - Prescriber Survey 75
5.7 About the Authors 76
5.7.1 Analyst 76
5.7.2 Reviewer 76
5.7.3 Therapy Area Director 77
5.7.4 Global Head of Healthcare 77
5.8 About GlobalData 78
5.9 Disclaimer 78

1.1 List of Tables

Table 1: Global Sales Forecasts ($m) for RA, 2013-2023 19
Table 2: Global RA Market - Drivers and Barriers, 2013-2023 22
Table 3: Key Companies in the RA Market, 2014 27
Table 4: AbbVie's RA Portfolio Assessment, 2014 30
Table 5: Pfizers's RA Portfolio Assessment, 2014 33
Table 6: Amgen's RA Portfolio Assessment, 2014 36
Table 7: JandJ's RA Portfolio Assessment, 2014 38
Table 8: Eli Lilly's RA Portfolio Assessment, 2014 40
Table 9: BMS' RA Portfolio Assessment, 2014 42
Table 10: UCB's RA Portfolio Assessment, 2014 44
Table 11: Roche's RA Portfolio Assessment, 2014 46
Table 12: GSK's RA Portfolio Assessment, 2014 48
Table 13: Novartis' RA Portfolio Assessment, 2014 50
Table 14: Sanofi's RA Portfolio Assessment, 2014 52
Table 15: AstraZeneca -MedImmune's RA Portfolio Assessment, 2014 54
Table 16: Astellas's RA Portfolio Assessment, 2014 56
Table 17: Vertex's RA Portfolio Assessment, 2014 58
Table 18: Daiichi Sankyo's RA Portfolio Assessment, 2014 60
Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 75

1.2 List of Figures

Figure 1: Global Sales for RA by Region, 2013-2023 21
Figure 2: Company Portfolio Gap Analysis in RA, 2013-2023 28
Figure 3: AbbVie SWOT Analysis in RA, 2013-2023 31
Figure 4: Pfizer SWOT Analysis in RA, 2013-2023 34
Figure 5: Amgen SWOT Analysis in RA, 2013-2023 36
Figure 6: JandJ SWOT Analysis in RA, 2013-2023 39
Figure 7: Eli Lilly SWOT Analysis in RA, 2013-2023 41
Figure 8: BMS SWOT Analysis in RA, 2013-2023 43
Figure 9: UCB SWOT Analysis in RA, 2013-2023 45
Figure 10: Roche SWOT Analysis in RA, 2013-2023 47
Figure 11: GSK SWOT Analysis in RA, 2013-2023 49
Figure 12: Novartis SWOT Analysis in RA, 2013-2023 51
Figure 13: Sanofi SWOT Analysis in RA, 2013-2023 53
Figure 14: AstraZeneca/MedImmune SWOT Analysis in RA, 2013-2023 55
Figure 15: Astellas SWOT Analysis in RA, 2013-2023 57
Figure 16: Vertex SWOT Analysis in RA, 2013-2023 59
Figure 17: Daiichi Sankyo SWOT Analysis in RA, 2013-2023 61

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

Remicade Biosimilar Market: By Type (Recombinant Non-Glycosylated Protein, Others), By Technology (MAb, rDNA, Others), By Service (Contract Research, CRAMS,Others), By Application (Blood Disorders, Oncology Diseases, Others), By Region-Forecast (2016-2021

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Globally, development of efficient and advance technology, higher expiration patent, rise in the awareness among people regarding remicade biosimilar, increasing government initiative across the globe, ...

Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...


Download Unlimited Documents from Trusted Public Sources

Biosimilar Industry in Europe

  • November 2016
    42 pages
  • Biosimilar  

  • Europe  

View report >

Pathology Statistics in Canada

  • October 2016
    2 pages
  • Biosimilar  

  • Canada  

    North America  

View report >

Global Breast Cancer Statistics

  • October 2016
    2 pages
  • Breast Cancer  

    Biosimilar  

  • Europe  

    World  

    Hungary  

View report >

Bioprocessing Industry

3 months ago

Biosimilar Statistics

3 months ago

Biosimilar Statistics

3 months ago

Related Market Segments :

Biosimilar

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.